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ALUMINUM SPECIATION AND BIOAVAILABILITY:
INVESTIGATIONS OF EQUILIBRIA BETWEEN ALUMINUM AND
CITRATE SPECIES IN PLASMA USING COMPUTER SIMULATION AND
"AL-NMR
Abstract:
Knowledge of the chemical species that aluminum forms in vivo allows assessment of
its potential availability to tissues and, thus, prediction of toxicity.  The major binders
of aluminum in serum are transferrin, an iron-transport protein (accounts for "90% of
aluminum in serum), and a number of ions, particularly phosphate and citrate.  In this
work, a number of published equilibrium models describing the speciation of
aluminum and citrate were prepared and used to predict equilibrium species over a
range of pH.  Qualitative NMR investigations confirmed the existence of an
asymmetrical trinuclear aluminum species (Al3Cit3(OH)4'^) that appeared rapidly (in
less than one minute after mixing the solution) and persisted over a wide range of pH.
A model by Ohman (1988) consisting of equilibrium constants for the
aluminum-citrate-hydroxide system was found to fit the observed data better than a
number of other published models describing the same system, based on predictions
made using Titrator, an equilibrium speciation program.  This choice was strengthened
by the observation that the starting pH of actual solutions agreed better with the
Ohman's model than with the others.  Ohman's equilibrium model was then
extrapolated (again, using Titrator) down to physiologic concentrations of aluminum
and citrate, which predict only charged (nonlipophilic) species at plasma pH and a
small amount of neutral aluminum-citrate complex at low pH.  Passive uptake into
tissues requires the existence of an uncharged aluminum species — these results
suggest that, based on the aluminum-citrate system, aluminum will not be taken up
passively from serum as a citrate complex, although it could if bound to some other
ligand not considered here (such as phosphate).  Furthermore, although concentrations
of aluminum and citrate relevant to gut contents were not considered here, the
presence of a neutral aluminum-citrate complex at gastrointestinal pH may be
important for predicting absorption into serum.
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I. Introduction
Aluminum is the most common metal on earth and some exposure to it, whether via
ingestion or inhalation, is inevitable.   Its toxicity (particularly neurotoxicity) is
currently hotly debated.   One of the central issues to be resolved with regard to
toxicity is the chemical forms of aluminum present in the blood.  This is important
because the various species of aluminum differ widely in their charge state and
solubility, which can determine how much of the metal is available to susceptible
tissues.  The physiologic behavior of aluminum is particularly difficult to assess
primarily because of a lack of a suitable radionuclide but also due to various other
analytical problems, not the least of which is contamination of samples by ubiquitous
aluminum-containing dusts.
Citrate, a common component of the human diet, binds aluminum and enhances the
absorption of aluminum from the gastrointestinal tract.  Once in the plasma, aluminum
is carried largely on transferrin, an iron-binding protein, with some 10% remaining in
a small-molecule form; citrate may still play a role here.  The relative availabiUty to
tissues of the protein-bound compared to the soluble forms of aluminum is unclear.
Analytical chemists have developed equilibrium models in an attempt to characterize
the plasma chemistry of aluminum, particularly with regard to citrate.  These models
were derived largely on the basis of theoretical curve-fitting of titiration data with very
littie direct observation of distinct chemical species. This report reviews the literature
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on the physiologic disposition of aluminum, describes experiments using "Al-nuclear
magnetic resonance as a direct probe of aluminum species, and compares the
agreement of published aluminum-citrate complexation models with the NMR data
obtained.  Finally, a best-fitting model is used to predict aluminum-citrate speciation
under physiologic aluminum and citrate concentrations.
II. Background
Exposure to some aluminum is unavoidable and occurs for the most part orally,
through food and water, although oral intakes are small because aluminum as a
component of minerals (the usual form of the element in nature) is of limited
solubility.   Inhalation constitutes a small fraction of aluminum exposure to the general
population, though it can be significant in some occupational settings.  Total daily
intake of aluminum is 30 to 50 mg on average to the population at large (Ganrot,
1986), of which less than 1 mg is from water (Jones and Bennett, 1986).
The species of aluminum (that is, the chemical forms that it takes) in the body have
important implications for the balance between the metal's uptake into tissues and its
excretion.   Aluminum is very insoluble except at exfremes or pH or in the presence of
chelating ligands.  To be taken up passively by tissues, it must be in the form of a
neutral molecule or complex; to be taken up actively, in contrast, it appears that
aluminum must be bound to a protein for which a specific receptor exists.
Insoluble aluminum hydroxide, which constitutes some antacids, for example, is
Al(OH)3 (s).  This mineral can form from the precipitation of aluminum from aqueous
solutions.  When dissolved, and at low pH, aluminum is in the form of AP"^ or
A^HjO)^''^.  As the solution pH increases, aluminum can form hydroxides (Al(OH)^+,
Al(OH)2+, Al(OH)3''(aq), and Al(OH)4') via successive loss of protons from the
associated water molecules.  Aluminum can also form complexes with small ions.
Citrate (Ci), a triprotic carboxylic acid, binds aluminum with high affinity to form a
variety of mono- and polynuclear aluminum species and mixed hydroxo species, such
as those listed here:
AlCi"
AlCiH^
AlCi^
AlCiOH-
AlCi(OHV
AljCijCOH),*- '
AljCijCOHV ^
Al^Ci^COHV
Aluminum also appears to complex strongly with phosphate to form AIPO4, A1HP04^,
A1H2P04'% Al2P04'^ AhVO.iOUV, and Al2P04(OH)3''. Citrate and phosphate appear
to be the most physiologically important small-ion ligands of aluminum.  In serum,
one or two aluminum ions can associate with each molecule of transferrin, which can
be taken up specifically by cells.
Some over-the-coimter pharmaceuticals such as antacids and buffered aspirin contain
sufficient aluminum to increase the daily dose significantly.  Many antacids consist of
a mixture of Al(OH)3 and other hydroxides, such as magnesium.  Some over-the-
counter antacid preparations (e.g., Maalox) contain 400 mg Al(OH)3 and 400 mg
magnesium hydroxide; the recommended dose for relief from gastric discomfort is up
to eight tablets per day—^that is, 3.2 g A1(0H)3,, or 1.1 g aluminum, a 20-40-fold
increase over the average exposure from food and drinking water alone.   Patients with
renal insufficiency are often administered large quantities of aluminum-containing
antacids in order to bind excess phosphate;  the resulting AIPO4 is an insoluble form
that makes the phosphate more easily excretable via the feces.
Aluminum has been measured in U.S. groundwaters at a range of 0.014 to 0.29 mg/1
and in untreated surface waters at 0.016 to 1.17 mg/1.  Aluminum sulfate is often
added as a flocculant to surface waters, resulting in aluminum concentrations in
finished drinking water from 0.014 to 2 67 mg/1.  Assuming average daily water
consumption of 2 1 results in an average daily intake of aluminum from water of 0.2
mg (Orme & Ohanian, 1990).
Dialysis patients can be exposed to large amounts of aluminum from their dialysis
fluid.  This exposure has been responsible for notable episodes of neurotoxicity.   Such
exposures have largely been eliminated, however, by deionization of fluids used to
make up dialysis solutions.
Inhalation exposure of the general population to aluminum in dust amounts to 0.14
mg/day based on an upper-bound measurement of 5000 ng/m^ (in urban air; Jones and
Bennett, 1986) and typical exposure estimates (1 1 air/breath and 20 breaths/min).  In
contrast, miners, smelters, and other metal workers can be exposed to toxic levels of
aluminum through dusts and aerosols.  Blinder et al. (1991) found that welders
exposed to 3.0-8.9 mg aluminum/m' excreted 107-351 /ig/l aluminum in the urine
and 18-29 iig/g was found in the bone.   Both workers had been welding for about 20
years.
Jones and Bennett (1986) estimate that ~3% of inhaled aluminum is absorbed into the
blood from the lung.  Volunteers exposed to < 1 mg aluminum/m^ (RoUin et al..
1991b) experienced increased serum aluminum concentrations compared to controls,
but urinary excretion was unchanged.  Exposure of rabbits to 0.56 mg aluminum/m^
over 5 months led to 15.8-fold increased accumulation of aluminum in lung compared
to controls, 2.5-fold increase in brain, and 1.65-fold increase in kidney (RoUin et al..
1991a).
The study of aluminum speciation has presented a number of major difficulties to
researchers.  No radionuclide of aluminum is readily available, obviating tracer
studies.  Because of its ubiquity in the environment, contamination of samples (such as
that from dust particles) is difficult to avoid.   Furthermore, the insolubility of some
forms of aluminum has caused problems in in vivo studies.
III.        Techniques for analysis of aluminum and its speciation in biological media
A. Atomic absorption
Total aluminum concentration of biological media is typically determined using atomic
absorption spectroscopy.   This method alone, however, provides no information about
speciation.  It is subject to contamination, since aluminum from dusts is difficult to
avoid.   Spectral interference from other metals (such as vanadium) can be avoided by
judicious choice of absorption lines.  The detection limit of flame atomic absorption
spectroscopy for aluminum is 30 ng/ml (1.1 fiM) (Skoog & Leary, 1992).  The
detection limit for elecfrothermal atomic absorption is considerably lower, 0.005
ng/ml, but this method has not been widely used in the applications described here.
B. High-energy-accelerator mass spectrometry
Day et al. (1991) described the use of ^*A1, a long-lived isotope (half-life ~10* years)
of aluminum, in a human tracer study performed with high energy accelerator mass
spectrometry.   Meirav et al. (1991) performed a similar experiment in rats.
C. Filtration techniques
Gel filtration and ultrafilttation, combined with atomic-absorption spectroscopy, of
serum or simulated serum solutions (designed to contain all the important serum
ligands for aluminum) have been employed to distinguish between protein-bound and
non-protein-bound aluminum and, to a degree, among different protems bound to
aluminum.  It is important to recognize that at high concentrations aluminum may
precipitate out as a solid or form a colloid that cannot be filtered.  These do not
represent protein-boimd aluminum, though it may not be possible to distinguish
between protein-bound and otherwise unfilterable aluminum.
A number of researchers have attempted to investigate how aluminum binds to serum
proteins using gel filtration techniques (Day eLal., 1991; Bertholf et al., 1984, 1985;
Rahman eLal., 1985; Favarato eLal., 1992a,b; Cochran eLal., 1985). This approach
has been problematic in a number of respects. Many columns avidly bind aluminum
themselves: Favarato et al. (1992a) recovered aluminum from different columns, by
washing with buffer containing desferrioxamine, in these amounts: TSK-GEL HW-
5SS, 75%; Sephadex G-200, 36%; Sephacryl S-500, 30%;and Bio Gel P-2, 24%.
In the absence of useful radionuclides of aluminum, the major analytical tool for
elucidating the distribution and pharmacokinetics of this element has traditionally been
atomic absorption spectroscopy (AAS).  The limitations of this method have already
been discussed.  Because of changes in speciation of plasma and aqueous solutions
with time, which tends to produce colloidal species that would not be expected in
vivo, filtration studies are often imreliable.  Accelerator mass specfrometry requires
extremely specialized equipment and is furthermore prohibitively expensive.  What is
needed is a method that can distinguish directly not only between protein-bound and
soluble species, but among species within both of these groups.   Datta et al. (1990)
attempted to develop a method to study aluminum speciation using HPLC and foimd
that the technique failed to distinguish among the small, soluble species, even those of
different charge.  Another method of studying aluminum kinetics separates aluminum
species into three categories, depending on the rate of reaction with ferron, a
colorimetric reagent, but does not identify individual species (Hundt and O'Melia,
1988; Jardine and Zelazny, 1987).
Recently, nuclear magnetic resonance (NMR) directed at the ^'Al nucleus has been
used to investigate aluminum species in solution.   Unlike "C or 'H, "Al has a spin
quantum number greater than 1, resulting in broad signals when bound to
asymmetrically arranged ligands, which makes structural assignments difficult.
Theory and applications of ^'Al-NMR have been thoroughly reviewed by Akitt (1989).
Fatemi et al. (1991) reported preliminary data from "Al-NMR demonstrating
aluminum binding to transferrin, albumin, and citrate.   For an aluminum-citrate
solution, these investigators found a double signal from pH 6.0 to pH 8.4 in the
region from about 0 to 10 ppm; at the highest pH, Al(OH)4" was detected as well.
Feng et al. (1990) detected a trinuclear aluminum-citrate species in solution over a
range of intermediate pH whose identity was confirmed by x-ray crystallography.
Further information on earlier NMR studies can be found in the Discussion section,
below.
IV.        Gross absorption of aluminum in the digestive tract
A commonly cited estimate of absorption of total aluminum from the gut of 0.1 to
0.3% (Ganrot, 1986) was based in part on the assumption that urinary excretion
proportionally reflects absorption, which does not take into account tissue distribution,
as discussed below.  An estimate closer to measured values is 1 % (based on data
reported by Jones and Bennett, 1986); results of Day et al. (1991) are also in
agreement with this estimate.
Some absorption of aluminum may occur in the stomach, as suggested by the results
of Rodger et al. (1991); however, the majority of aluminum absorption is expected to
occur in the intestine.  The general, two-step absorption process in the gut is (1)
lumen— > mucosa and (2) mucosa— > bloodstream.  Aluminum must be in the form of
neutral complexes in order to be absorbed by diffusion through the plasma membrane
of cells.  Ionic aluminum may be absorbed actively by specialized iron-absorption
pathways in the gut, as discussed below.
The most important aspect of the digestive tract with regard to its uptake of aluminum
is its change in pH, from 2-3 in the stomach to 3-8 in the small intestine.  The low
pH of the stomach allows for complete dissolution of, for example, A1(0H)3 in
antacids.  This dissolution forms free aluminum (AP^) that is thus made available for
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complexation and possible absorption.  Studies of intestinal uptake that fail to specify
or control for pH must therefore be considered unreliable.
A. Animal studies
Domingo et al. (1991) examined citrate and other organic acids (ascorbic, gluconic,
lactic, malic, oxalic, and tartaric) for their effect on aluminum absorption.  These
investigators administered aluminum to rats by gastric intubation and monitored
urinary and tissue aluminum.  Each of these acids has fewer dissociable protons than
citric acid, and, for the most part, promoted tissue accumulation of aluminum to a
lesser degree than citrate.  Ascorbic acid's effect on tissue accumulation of aluminum
was found in this study (though not in others) to be similar to that of citric acid.
Organic acid-induced urinary excretion of aluminum would provide further evidence
of increased gastiointestinal absorption, but in this experiment no significant changes
in urinary aluminum were found as a result of administration of the organic acids
studied.
B. Human studies
The effect of gastric pH on absorption of aluminum was examined by Rodger et al.
(1991).  These investigators administered either placebos or ranitidine, a drug that
suppresses production of stomach acids (and would, thus, elevate gastric pH), to
healthy subjects and to patients with renal disease, prior to administration of Al(OH)3.
The subjects who received placebos had higher levels of urinary excretion of
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aluminum than those that received ranitidine, implying that low gastrointestinal pH
promotes absorption of aluminum.
It has been suggested that Alzheimer's disease (AD) patients might have a genetic
tendency to absorb excessive amounts of aluminum.   To test this hypothesis, Taylor et
al. (1992) administered an aluminum citrate-containing drink to 20 AD patients and 20
age- and sex-matched controls, measuring blood aluminum before and after
consumption of the drink.   The investigators found a greater increase in blood
aluminum among younger AD subjects than controls, but not among the older AD
subjects compared to their controls.  This study could have been improved by a study
population large enough to allow sufficient statistical power for stratified analysis or
randomization.  Furthermore, as has been reported elsewhere, there was considerable
variability among measured serum aluminum concentrations, which could have been
either a contamination problem or the result of confounding by unstratitied exposure
variables.
The measurement of total aluminum concentration in urine before and after exposure
is the simplest means of assessing absorption.  Cobum et al. (1991) administered 950
mg calcium citrate four times daily and 2.4 g/day A1(0H)3 as an antacid to eight
normal men.  Baseline aluminum excretion was 0.02 + 0.004 /xmol/mmol creatinine;
excretion mcreased somewhat upon ingestion of Al(OH)3, but was much higher (by a
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factor of 5.3 to 11.1) when calcium citrate and A1(0H)3 were ingested together,
compared to AlCOH), alone.  Similar results were obtained by Walker et al. (1990),
who foimd that sodium bicarbonate had less of an effect than sodium citrate on
aluminum excretion; and Nolan et al. (1990), who found that calcium acetate
increased urinary aluminum excretion much less than did calcium citrate.  Maximum
urinary excretion of aluminum, after coadministration with calcium citrate, was 176 ±
103 fig/g creatinine/day compared to 6 + 3 when only Al(OH)3 was taken (Nolan et
al., 1990).
House et al. (1992) examined risk factors for elevated serum aluminum in a group of
71 office workers and found higher serum aluminum to be associated with antacid
consumption and with the batch in which the sample was analyzed, which strongly
suggests blood-sample contamination problems.  Consumption of cola drinks from
aluminum cans appeared to be inversely related to serum aluminum, but this was
believed, again, to be an artifactual result of the high variability due to contamination.
V. Mechanisms of aluminum absorption from gastrointestinal tract
A.        Role of active transport and iron absorption pathways
Feinroth et al. (1982) examined absorption of aluminum using a rat everted gut-sac
model. The pH of the bath in which the intestines were bathed was 7.35-7.42.
Absorption was inhibited by dinitrophenol, and by absence of glucose, both of which
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inhibit cellular respiration, sfrengthening the hypothesis of active fransport of
aluminum out of the intestine.
Since aluminum behaves similarly to iron in many biological systems (for example
binding to transferrin, discussed below), AP^ may also be taken up via the specialized
iron absorption pathways found in the gut.  As evidence for this hypothesis, iron
deficiency has been found to increase the absorption of aluminum both in rats
(Cannata et al.. 1991) and in renally impaired humans (Huang et al., 1992).
Andersen et al. (1987), in confrast, found that administering exfra iron orally to
dialysis patients did not prevent absorption of aluminum from phosphate binders.  Van
der Voet et al. (1987), in an excised gut-section model, found that Fe^*^ enhanced
disappearance of aluminum from the intestinal lumen, but did not increase systemic or
portal blood aluminum; that is, it did not increase absorption overall.  Fe^"^, in
confrast, did not cause disappearance of aluminum from the intestinal lumen.
An iron-binding protein has recently been identified in the duodenal mucosa of rats
and humans that may prove to bind to aluminum as well, and may thereby account for
part of the mechanism of aluminum's uptake from the gut (Conrad et al., 1992).  The
protein, named mobilferrin after the Alabama city in which it was discovered, is
biochemically and immunologically distinct from both ferritin and fransferrin, the two
major iron-binding proteins in blood, as assessed by molecular size, elecfrophoretic
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mobility, and amino acid composition.  The dissociation constant for iron from
mobilferrin was found to be 8.92 x 10^.  The physiologic role of this protein is not yet
known; to date it has only been isolated from duodenal homogenates.
^. Role of citrate
Citrate, the polyanion of triprotic citric acid, forms stable complexes with AP"^,
including a neutral molecule (AlCi") that can be absorbed into the blood.  Cifrate is
believed, for this reason, to be the most important small-molecule coraplexing species
commonly found in the diet, and many experimental investigations have confirmed
this prediction.  Furthermore, citrate is present in serum at 99 fiM, at least 100-fold
higher than the concentration of aluminum.
Van der Voet et al. (1989) found that citrate-enhanced absorption of aluminum was at
least in part an energy-dependent process, based on their observation that
administration of dinitrophenol, an uncoupler of oxidative phosphorylation, decreased
the citrate-mediated disappearance of aluminum from the intestinal lumen.
Froment et al. (1989), in an examination of the mechanism of enhancement of
aluminum uptake by citrate, tested the hypothesis that citrate increases the
permeability of the tight junctions between intestinal epithelial cells.  The investigators
excised the duodena of live rats, added a solution of ruthenium red, and filled each
gut section with either aluminum chloride or aluminum citrate.  On examination of the
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isolated duodenal sections by transmission electron microscopy, infiltration of
ruthenium red through the tight junctions was observed in the presence of aluminum
citrate.  In addition, aluminum citrate was found to decrease the transcellular electrical
resistance of tight junctions.  The investigators did not examine the effect of citrate
alone, however.
VI.       Aluminum in blood
Because of the high concentration of potential ligands relative to the concentration of
the metal, aluminum is expected to be soluble at blood concentrations up to at least
100 /ig/1.  Ganrot (1986), based on more than 50 literature sources, reported that the
most credible values for serum aluminum are in the range of 1 to 5 /xg/l, or 0.037-
0.185 /iM, assuming that values much higher than this stem largely from
contamination.  More recently, Wang et al. (1991) measured levels of aluminum in 63
Canadians by Zeeman atomic absorption spectroscopy and found an average of
0.06+0.05 ^M in serum and 0.20+0.10 /jlM in urine.
A.        Nature and amounts of carrier molecules
Although many of the organic ligands found in the gut are also found in the blood
(Table I), the major plasma binder of aluminum is transferrin, an iron-transport
protein that also specifically binds aluminum.  Some nonspecific aluminum binding
may also take place with albumin, and at least one other aluminum-binding protein has
been postulated (Canavese et al., 1986; Favarato et al., 1992b).
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Albumin 630 ^M Histidine 77.0 fiM
Cystine 10.9 /xM Lactate 1.51 mM
Citrate 99.0 ^M Oxalate 9.20 fiM
Cysteine 33.0 fiM Phosphate 1.10 mM
Glycine 2.30 mM Sulfate 330 juM
Glutamate 60.0 nM Transferrin 31 fiM*
Table I.  Concentrations of components in serum available to bind with aluminum
(from Harris, 1992)
*total binding capacity: two binding sites per molecule, minus sites occupied by iron
Transferrin, which appears to be the major ligand for aluminum in serum, is a protein
of 96,000 daltons.  It is similar in size and amino-acid sequence to albumin, but binds
metals (particularly iron) with high specificity at two independent binding-sites with
similar metal-binding aifinities.  Binding of a trivalent metal ion to transferrin
involves deprotonation of three tyrosine residues and concomitant binding of a
bicarbonate ion (which is not limiting in serum).  Transferrin is normally 30%
saturated with iron (Cochran et al.. 1984).   Its usual concentration in serum is 37 /xM
(Harris, 1992), giving 49 fiM of total binding sites based on two sites per molecule
and 30% saturation with iron.  Dialysis patients have been found to have less, about
30 ^M (Cochran eLal., 1984).
B. Binding to serum proteins
Perez Parajdn et al. (1989) have evaluated two ultrafiltration methodologies (Amicon
Diatlo YMIO and DDS GR61PP) for in vitro fractionation of aluminum;
contamination was a large problem in both.  These investigators found, using
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ultramicrofiltration with Amicon MPS-1 systems, that 8.3% of serum aluminum from
normal subjects and 13.3% of that from uremic patients was ulfrafilfrable.
"Ultrafiltrable" as used here means able to pass through an ultrafilter, and refers to
small-molecule species such as aluminum-cifrate species; nonultrafilterable species are
primarily protein-bound but may also include insoluble or colloidal complexes of
aluminum hydroxide, for example.
Yokel and McNamara (1988) found that ultratilterable aluminum was higher in the
serum of renally impaired rabbits than in serum from renally competent animals, after
incubation of aluminum with rabbit serum in vifro and after an intravenous dose of
100 fimoUkg.  These investigators also compared the solubilities (in terms of their
ultrafilterability) of different aluminum salts in bicarbonate buffer, and foimd that the
citrate salt of aluminum remained completely ulfrafiltrable up to a total aluminum
concentration of 1 mg/ml, while aluminum chloride, nifrate, and lactate salts
decreased in solubility when total aluminum exceeded 1 /xg/ml.   The concentrations at
which aluminum was not totally ulfrafilterable were above the high end of the
expected range of serum concentrations.  Two of the rabbits in this study were
reported to have died prematurely, possibly (according to the authors) from kidney
stones, which could conceivably have consisted of precipitated aluminum.
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The similar sizes of transferrin and albumin make it difficult to separate these proteins
chromatographically, and failure to add bicarbonate to the elution buffer can decrease
or prevent binding of aluminum to transferrin.  Many authors have assumed that
aluminum binds to both, although some evidence suggests that binding to albumin is
insignificant, as discussed below.  Martin et al. (1987), based on weak binding in
vitro, knowledge of high competition in vivo for albumin binding sites, and generally
low affinity of metal ions for albumin, argue against significant in vivo binding of
aluminum to albumin.   This would be particularly true under uremic conditions, where
potential binding sites on albumin are likely to be occupied by other ligands that
accumulate in serum.
Day et al. (1991) administered a dose of 100 ng ^Al and about 1 /ig "Al (natural
aluminum) in sodium citrate solution to a human volunteer.  The highest plasma ^*A1
concentration measured was 0.3 ng/1 at 6 hours post-ingestion, which represents about
1 % of the administered dose (assuming a plasma volume of 3 1).  The study
confirmed, by gel permeation chromatography and anion exchange chromatography at
pH 7.4, that 80% of aluminum in plasma was associated with transferrin, 15% existed
as other high-molecular-weight (>5 kDa) complexes (including albumin), and 5% as
low-molecular-weight species.  Ion-exchange chromatography, however, may cause
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redistribution of ionic aluminum among proteins, so the findings of protein-specific
binding are not reliable.
Favarato et al. (1992b) compared the protein binding of aluminum among renaUy
competent workers exposed and unexposed to aluminum and detected a novel protein,
dubbed albindin.  This protein picked up more than 40% of serum aluminum after
treatment of the serum with desferrioxamine (a high-affinity chelator of aluminum)
and its amino-acid profile was distinct from that of transferrin or albumin (Favarato et
al., 1992a).  The protein-binding profile of aluminum was most complex in the more
highly exposed group of workers (classified on the basis of total serum aluminum
content). Proteins were identified by polyacrylamide gel electrophoresis (SDS-PAGE),
a technique which did not resolve transferrin and albumin (Favarato et al., 1992b).
Cochran et al. (1985) eluted plasma (spiked with aluminum) from uremic patients on
Sephacryl S-300 and assessed the reproducibility of the aluminum/transferrin and
aluminum/albumin molar ratios in adjacent elution fractions.  They found that the
aluminum-to-fransferrin ratio remained at about 0.12, whereas aluminum/albumin
varied from 0.024 to 0.002, providing evidence for an association between aluminum
and transferrin, but not albumin.  Transferrin and albumin concentrations were
assessed by immunodiffusion, but the methods used were neither described nor
referenced.  The overall recovery of aluminum was not reported for this experiment.
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so the significance of the experiment's results is uncertain.  Dialysis of purified
albumin against aluminum solution resulted in the association of 10% of the aluminum
with albumin, but when calcium and phosphate were added, the association between
albumin and aluminum could no longer be detected.  There was no evidence of
association of aluminum with either a Sephacryl S-300 or Sephadex G-50 gel.
C. Role of transferrin
In vitro analytical chemical methods such as titration have been used to estimate the
affinity of aluminum (and other metals) for transferrin and other potential chelators
found in serum.  Transferrin's affinity for iron is considerably higher than for
aluminum (e.g., log 62=40 for Fe^"^ and 31 for AP"^; Marques, 1991).   Since
aluminum is present in small amounts in the blood relative to iron, and since iron
normally occupies only 30% of transferrin, aluminum binding to transferrin is not
expected to be limited by either levels of transferrin (concentration in blood 37 jxM;
Harris, 1992) or of iron.
Evidence for transferrin's role as an aluminum carrier is strengthened by a study that
showed aluminum levels in urine and brain to be increased in rats depleted of iron and
exposed orally to aluminum (Cannata et al.. 1991).  This phenomenon occurs because
reduced iron stores lead to increased production of transferrin (Prasad, 1991;
Klausner, 1988), a central concept in iron homeostasis.  In fact, Cannata et al. found
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that iron-depleted rat intestinal epithelial cells in vitro took up significantly more
aluminum when exposed to transferrin-boimd aluminum than did normal cells.
Although useful as a predictor of uptake of aluminum into tissues in general, this
evidence is not specifically relevant to uptake by the intestine, since transferrin is not
found in the intestinal lumen.
VII.      Kinetics of uptake by cells
Several investigators have examined the uptake kinetics of transferrin and iron by
cells.  Cole and Glass (1983) found that at iron concentrations up to 50 ^M, binding
of iron to transferrin was not saturated.   Iron uptake by mouse hepatocytes increased
with increasing transferrin concentrations, but nonspecific uptake (pinocytosis and/or
diffusion) accounted for 10-20% of uptake.  Dissociation constants of 0.081 fiM (for
suspended cells) and 0.29 fiM (for plated cells) were reported for dissociation of
transferrin from cells.  Page et al. (1984) found similar results using cultured rat
hepatocytes.   Cochran et al. (1991) examined the competition of aluminum and iron
for transferrin binding and uptake in reticulocytes (immature red blood cells).  Binding
was significantiy stronger in these cells (K^^^S /xM) than Cole and Glass reported
for hepatocytes.  Fiuthermore, radiolabeled aluminum-transferrin (5 fiM) was taken
up 1.8 times faster than radiolabeled iron-transferrin.  Iron uptake reached a plateau
by 40 minutes; aluminum uptake, in contrast, continued to increase after 40 minutes.
In addition, uptake of radiolabelled iron-transferrin was inhibited to a greater extent
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by addition of unlabelled iron-transferrin) than by addition of aluminum-transferrin.
The authors postulate a post-uptake feedback mechanism to regulate uptake of iron,
which does not appear to have an effect on uptake of aluminum.  McGregor et al.
(1991) reported that aluminum was taken up to a greater degree from solutions of
AICI3 than of aluminum and citrate, possibly because, at physiologic pH, uncomplexed
aluminum would be expected to be hydrolyzed to colloidal Al(OH)3, in contrast with
aluminum citrate, which apparently does not form uncharged species at physiologic
pH (see section on speciation, above).
Interestingly, in contrast to the results of Cochran et al. (1991), in human
erythroleukemia K562 cells, transferrin-bound aluminum down-regulated the number
of cell-surface transferrin receptors to a greater degree than iron did (McGregor et al..
1990).  It is possible that hepatocytes possess a regulatory mechanism for transferrin
receptors different from that in cultured leukemia cells, or there may be an
interspecies difference, since Cochran et al. used rat hepatocytes.
VIII.     Pharmacokinetics
Upon gastrointestinal absorption (or intraperitoneal injection) aluminum travels via the
portal circulation into the liver, where it is thought to undergo a first-pass clearance;
that is, much is removed from the bloodstream (Xu eLaJ., 1992).  The effectiveness
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of this process is evident from high levels of aluminum found in the liver relative to
peripheral organs (such as brain and bone) (Xu et al.. 1992).
Much of the work done thus far on aluminum speciation and distribution has looked at
exposures other than ingestion, such as intravenous or intraperitoneal injection, which
bypasses the firast-pass effect of the liver.  Exposure to dialysis fluid can be
considered analogous to intravenous injection since the bloodstream is directiy
exposed, bypassing the first-pass effect of the liver.
A. Excretion routes
1.     Urinary excretion
Aluminum is excreted primarily in the urine, as described above, and to a small
degree in the feces (largely as insoluble aluminum phosphate) by way of the portal
circulation, liver, and bile (< 1%; Xu et al.. 1991).  The relative contributions of
each depend in part on such factors as solubility of aluminum, presence of dietary
constituents such as citrate and phosphate, renal competence, and dose of aluminum.
Braunlich et al. (1986) investigated the possibility that renal excretion of aluminum
was connected with nephrotoxic effects and found that aluminum administration in rats
(1) resulted in a loss of urine-concentrating ability and (2) increased excretion of p-
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aminohippuric acid, both of which were considered to represent toxicity.
2.     Biliary excretion
Biliary excretion is apparentiy not a major route of clearance of aluminum.  Xu et al.
(1991) found that it accounted for < 1% of doses administered to rats, whereas
urinary clearance accounted for between 9 and 17%.
B. Animal data
Fulton and Jeffery (1990) examined the effect of dietary citrate or ascorbate on the
absorption of aluminum from drinking water and on its subsequent distribution and
excretion.  They found a dose-dependent increase in aluminum concentration in bone,
stomach, intestine, and kidney; liver aluminum was 1.5-fold greater than controls, but
there was no dose-response, and no uptake into brain was observed.  Ascorbate and
citrate increased the concentration of aluminum in tibia, plasma, urine, and feces.
Plasma aluminum (about 0.7 fiM) was found to constitute less than 0.5% of total
blood aluminum, which is inconsistent with other studies and particularly surprising
given that transferrin is a plasma protein.   Red-blood-cell aluminum as found not to
vary with dose of aluminum, whereas plasma aluminum did, which is consistent with
other studies.  Plasma aluminum concentrations were within the range of values
reported by other studies (Ganrot, 1986).
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C. Human data
Alfrey et al. (1980) found that nondialyzed uremic patients experienced aluminum
burdens in liver at 6.3 times, spleen at 12 times, bone at 6.2 times, and brain at 1.7
times higher than renally competent patients; dialyzed uremics and, in particular,
dialyzed uremics suffering from encephalopathy, had tissue burdens many times higher
than nondialyzed uremics.
D. Uremia
Uremic (renally impaired) animals and humans seem to be more susceptible to
aluminum accumulation and toxicity than renally competent subjects, even in the
absence of dialysis.  Hosokawa and Yoshida (1989) performed 5/6 nephrectomy on
rats and collected serum three months later, without administering additional
aluminum above the normal dietary exposure. They found that the average
concentration of aluminum in serum was more than 10 times that seen in renally intact
rats, and the concentration in kidneys was about 10 times higher.  Arieff et al. (1979)
obtained results similar to Alfrey's human data for deposition of aluminum into liver
of nonuremic dogs and uremic compared with nonuremic rats but, in contrast, found
that brain aluminum was higher in nondialyzed than dialyzed chronic renal failure
patients.  The aluminum content of the dialysis fluid was not reported.
It would be instructive to perform a study in which long-term aluminum burden in
brain, bone, and liver were assessed in uremic and nonuremic rats or rabbits after
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chronic low and moderate oral exposures, in combination with a short-term kinetic
study. Such a study would elucidate the effects of acute vs. chronic exposures and
kinetics on body burden.
There are a number of possible reasons for the observation that uremia leads to an
increased body burden of aluminum.  The simplest explanation is that, in having
lower excretory capacity, uremics might simply not be able to rid themselves of
aluminum efficiently, allowing it more time to be distributed to peripheral tissues.
However, a number of recent studies have demonstrated that uremic animals actually
have higher renal (and systemic) clearance of aluminum than renally competent
animals (Yokel & McNamara, 1988; Meirav etal., 1991; Ittel eLal., 1991; Wilhelm
etal.. 1989).
The aluminum toxicity experienced by uremics may be iatrogenic, through exposure to
aluminum in dialysis fluid, which is equivalent to intravenous administration of
aluminum.   This possibility has already been addressed in the clinical setting:  dialysis
fluid is now made from low-aluminum water, and patients appear to suffer less
aluminum toxicity as a result (Ganrot, 1986).
The increased excretion of aluminum in uremia suggests that the free, or ultrafiltrable,
fraction is increased relative to the protein-bound fraction.  It is plausible that in
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uremia potential aluminum-binding sites on transferrin (and possibly albumin or some
other protein) are more likely to be tied up with competing molecules that accumulate
in the blood.  Renal clearance of aluminum would thus be expected to increase with
time after onset of uremia, as competing ligands accumulate, but this hypothesis has
not been investigated.
As discussed above, renal clearance of aluminum is higher in uremics than in normal,
renally competent individuals as investigated by pharmacokinetic studies.  Given that
uremics also experience higher aluminum tissue burden and toxicity, and have a
higher non-protein-bound fraction of aluminum, it appears that this fraction might be
more available to tissues than the protein-bound fraction.  The only other explanation
is that tubular reabsorption of aluminum occurs to a greater degree in uremics, but
this possibility has not been examined.
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Chasteen (1977) reported that serum transferrin concentration in dialysis patients is
about 30 (iM.  Given that serum aluminum concentrations are elevated in these
patients compared to normal individuals, this reduction in aluminum-binding capacity
may have implications for aluminum speciation.
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IX.        Tissue distribution
Bone, spleen, and liver are the primary organs of aluminum deposition (Ganrot,
1986).   Patients with renal failure frequentiy suffer from osteomalacia and have been
shown to have deposits of aluminum in the bone.  Recentiy, Goodman and O'Connor
(1991) found in chick embryos that 10 and 100 fiM aluminum decreased calcium
uptake into bone from 76 to 38% of controls, respectively, during 24-hour
incubations.  Brown and Schwartz (1992) reported increased deposition of aluminum
in liver and spleen of rats in response to dietary iron depletion.
A. Brain
The blood-brain barrier is normally permeable only to small, uncharged molecules.
Since much of blood aluminum appears to be complexed with proteins, it is unlikely
to permeate the blood-brain barrier directiy, although transferrin-receptor-mediated
uptake is a possible mechanism (Roskams and Connor, 1990).   In the presence of
other, smaller complexes, however, aluminum could cross the blood-brain barrier.  A
case study was reported of several renal dialysis patients suffering from bone
aluminum toxicity who were treated with desferrioxamine, an iron-chelating drug that
also efficiently chelates aluminum. The subjects experienced neurological symptoms
resembling dialysis dementia; several of them died.   The investigators conjectured that
the resulting desterrioxamine-aiuminum complex, much smaller and more soluble than
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aluminum-protein complexes, had been absorbed into the brain (Sherrard et al.. 1988).
Yokel et al. (1991a) supported this hypothesis in a rat study using microdialysis
probes to monitor aluminum-desferrioxamine diffusion into various tissues, including
the brain.
Allen and Yokel (1992) used in vivo microdialysis to compare the permeabilities of
aluminum and gallium through the blood-brain barrier (with a view to using gallium
as a model for aluminum) and found them to be dissimilar.  Gallium, although
attractive because it possesses useable radioisotopes, therefore does not seem an
appropriate model for aluminum penetration of the brain.   Specifically, these
investigators found that aluminum permeates the brain primarily at the cerebral
capillaries, whereas gallium permeates equally at the cerebral capillaries and at the
choroid plexuses.  Aluminum's permeation was nonsaturable, suggesting a nonspecific
absorption process such as diffusion rather than binding of aluminum-transferrin to
cell-surface receptors.   The absorption could, however, be a combination of specific
and nonspecific processes and still appear nonsaturable overall, so involvement of
transferrin cannot be ruled out.
Farrar gLal- (1990) found, using HPLC and gel electrophoresis, that binding of
radioactive gallium (which they presumed to be analogous to aluminum) to transferrin,
was lower in humans with either Alzheimer's disease or Down syndrome than in
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normal humans.  The authors postulate that reduced binding of gallium and,
presumably, aluminum to transferrin could lead to increased uptake by the metal
across the blood-brain barrier as a neutral citrate complex.  As discussed above,
aluminum does appear to be taken up in a nonsaturable fashion (i.e., nonspecifically)
at least at the cerebral capillaries (Allen and Yokel, 1992).
Roskams and Connor (1990) examined the binding of aluminum-transferrin and iron-
transferrin to homogenized rat brain and found evidence of a receptor that binds both.
Dissociation constants (K^) were 5.7 nM for Fe-transferrin and 13.1 nM for
aluminum-transferrin.   The affinity of this receptor for aluminum-transferrin, although
lower than that for Fe-transferrin, is still higher than the affinity of receptors in other
cells (such as hepatocytes and lymphocytes) for Fe-transferrin.   Unfortunately,
homogenized rat brain is probably not a good model for the blood-brain barrier.
These authors suggested that aluminum's toxicity in the brain might involve, at least
in part, disruption of normal iron homeostasis and iron-dependent cellular processes in
the brain.  Fleming and Joshi (1991) found that aluminum can interfere with the rate
of binding of iron to ferritin, an iron-storage protein.  This finding supports Roskams'
and Connor's suggestion.
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B. Fetus
Yokel (1985) found evidence to suggest placental transfer of aluminum.  Gomez et al.
(1991) reported that fetuses of pregnant rats exposed orally to A1(0H)3 concurrently
with citrate experienced higher than normal skeletal malformations, demonstrating
either that aluminum crosses the placental barrier directly or, possibly, that there is
some sort of indirect systemic effect on the mother.
Cranmer et al. (1986) found that intraperitoneal administration of AlCl, at doses from
100-200 mg/kg-day to gestating mice resulted in 6-10-fold increases over controls in
placental and 2-3-fold increases in fetal aluminum.  Oral gavage of 200 or 300
mg/kg-day led to less than a two-fold increase over controls in placental or fetal
aluminum.  No dose-response relationship was evident among any of the experimental
groups.
C. Milk
Yokel and McNamara (1985) found that, in rabbits, subcutaneous injection led to
excretion of 3.3% of the absorbed dose in milk, while intravenous administration led
to only 2.4%.  The maximum serum concentration in the pups was 185 /iM after a
dose of 40 jLimol/kg by intravenous administration to the dam.
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X. Equilibrium modeling
Equilibrium models, based on potentiometric data, allow a much more complete
(though theoretical) description of species formed in aqueous solutions of aluminum
with its ligands, compared to the analytical techniques described in earher sections.  In
this technique, fonnation (or equilibrium) constants are fit to data on change of pH as
a function of acid or base added to a solution.  These constants can then be used       '
(usually with a computer program) to predict equilibrium concentrations of the
postulated species under specified concentrations of aluminum and its ligands and at
different pH.
Berthon and Dayde (1992) described a model of aluminum speciation in the intestine
designed to compare the fraction of neutral aluminum species formed after
administration of either aluminum phosphate or aluminum hydroxide.  This model
found A1(0H)3 to dissolve better than AIPO4 in the presence of organic acids, and to
complex with the acids better; therefore, aluminum administered orally as A^OH),
would be better absorbed in the gut than AIPO4 and thus lead to the observed
increased relative toxicity.  Furthermore, this dissolution, complexation, and
absorption should be higher in the proximal jejunum (ca. pH 7) than in the duodenum.
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Bertsch and Anderson (1989) studied the speciation of the aluminum-citrate system
using ion chromatography and found that only two peaks were eluted, one containing
hexaaquo (fully hydrated) aluminum and the other apparently containing neutral
aluminum citrate and AlHCit"^.   Other singly charged species were not distinguishable
from the second peak and, presumably, more highly charged species were
undetectable.   Citrate complexes were highly sensitive to changes in ionic strength.
Ohman (1988) performed a titration study of aluminum-citrate speciation over time in
aqueous solution that followed pH as a function of added base.  Speciation was
calculated by curve-fitting using published equilibrium constants.  Two species (A1(H
'Cit)"' and A1(0H)H 'Cit)^) were found to exist at physiologic pH in fresh (that is,
unaged) solutions, and a third (Al3Ci3(OH)4'^) formed in somewhat older solutions.
On the basis of a similar pH-time study, Ohman (1988) first fitted stability constants
for AlCiH(H') and A10H(H"'Ci)^ at time 0 assuming that the concentration of
Al3Ci3(OH)4'^ was zero.  He then predicted corresponding concentrations of the
trinuclear species, based on the amount of hydroxide taken up, as evidenced by the
pH, then constructed distribution diagrams over time.  In these models, the trinuclear
aluminum species appeared after 1 minute at around pH 6 and then came to
predominate over a broader pH range after a few minutes (Fig. 1).
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Motekaitis and Martell (1984) examined potentiometrically the equilibrium between
aluminum and a number of organic ligands, including citric acid, at metal:ligand ratios
of 1:1 and 1:2.  Equilibration times between additions of acid or base varied, but
were not reported.  Only three species were assumed, each of them a 1:1
aluminum:citrate species in a different protonation state.
Gregor and Powell (1986) assumed that citrate's hydroxy proton was available to
complex with aluminum, and used a 5.3- or 6.3-fold excess of ligand over metal for
potentiometric determinations.  K^-cit' ion pairing was taken into accoimt since KOH
was used as a titrating base.  Eight aluminum-citrate species were assumed, but no
polynuclear species. "C-NMR was used to examine the identity of species, and
supported the possibility that the hydroxy proton was used in bridging.
Martin (1986) used adjusted equilibrium constants from the published literature to
model the binding of aluminum and cifrate at ionic strengths from 0.1 to 0.16 M, and
over a pH range of 1 to 9.  He assumed no polynuclear species were involved. At
physiologic pH and a ratio of 100:1 citrate to aluminum, the species AlCiOH'" was
predicted to predominate.
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Venturini and Berthon (1989) examined the aluminum-citrate equilibrium at
physiologic ionic strength and devised a model containing seven citrate species,
including a trinuclear and a binuclear aluminum species, and two hydroxy aluminum
species.  At physiologic pH and about 60:1 citrateialuminum, AlCijCOH)'^ and
AlCi2(OH)2^ predominated, while the trinuclear aluminum species (stoichiometrically
equivalent to that postulated by Ohman) predominated at physiological pH at
citrate:aluminum ratios of about 5:3 and 6:1.
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Recentiy, a handful of studies have appeared arguing for aluminum-phosphate species
as the predominant small-molecule form of aluminum in serum.  Dayde et al. (1990)
an titrated acidic aluminum-chloride/orthophosphoric acid mixture at different mole
ratios over a wide range of pH to derive formation constants; the aluminum-phosphate
species best fitting tiie model were taken to be AIPO4, A1HP04% A1H2P04*% MiPO^^\
Al2P04(OH)2^, and Al2P04(OH)3''.  A model constructed from these formation
constants and those previously determined for aluminum citrate and hydroxide
predicted the predominant low-molecular-weight species, under physiologic conditions,
to be AKOH)," (51%), AIPO4'' (41.5%), and Al2P04(OH)2^ (7.2%).
Harris (1992) reported a largely different set of equilibrium constants for the
aluminum-phosphate system based on linear free-energy relationships.  The two
species judged to be most important in serum were AIPO4OH' and AIPO4''.  This study
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developed a speciation model containing all ligands found in serum that are expected
to complex appreciably with aluminum, as well as metal ions (Zn^^, Ca^*, and Mg^^)
that compete with aluminum for binding sites on transferrin.  The model was studied
at aluminum and ligand concentrations typical of normal or uremic plasma and pH
7.4.  The following assumptions were made: (1) the n-terminal binding site on
transferrin is 60% saturated with iron, which is not displaced by other metals; (2)
aluminum does not bind to albumin; and (3) trinuclear aluminum citrate
(Al3Cit3(OH)4'^) and aqueous Al(OH)3 exist.   Concentrations of organic ligands in
normal serum were taken from the Geigy Scientific Tables, and formation constants
(other than for phosphate) were adopted from a number of literature sources and
averaged when more than one was available.  The principal species predicted from the
complete model were aluminum-transferrin (about 81%), AIPO4OH (about 16%), and
a few hydrolyzed species.   Harris' work is the first published so far to incorporate
cifrate and phosphate in the same equilibrium model, and the first to suggest that
phosphate might be a more significant binder of aluminum than citrate.   (See
Appendix for a listing of the equilibria considered in this model.)
Citrate and phosphate are both in large excess relative to aluminum (about 10(X)-fold),
so any competing ligand(s) would have to be major ones to have much effect on the
models.  Harris (1992) acknowledges the confroversy over the existence of A1(0H)3
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(aq), but assumes that the solid dissolves to produce the aqueous form, rather than the
component ions which, again, is in question.  Again, though, this species is not
predicted to constitute a major sink for aluminum.
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XI.        Methods
The purpose of the experiments and modeling peif ormed here was to predict whether
any neutral, small-molecule complexes of aluminum and citrate exist in appreciable
quantities under physiologic conditions that could represent a source of aluminum in
plasma available for passive uptake of the metal into tissues.  We attempted to identify
individual aluminum-citrate species using "Al-NMR as a direct probe.   Further, we
characterized the aluminum-citrate system potentiometrically and stoichiometrically by
looking at starting pH and change of pH over time, and by titrating with strong base.
We then used an equilibrium-speciation computer program, called Titrator (Cabaniss,
1987), along with published sets of equilibrium constants, to predict distributions of
aluminum species in the aluminum-citrate system at mole ratios similar to those used
in the experiments.  We compared the experiments with those of the models and
selected a model that best fit the NMR spectra and the potentiometric data; this model
was then extrapolated to physiologic conditions to predict the distribution of aluminum
species expected in vivo.
The models described below were developed on the basis of equilibrium constants for
the aluminum-citrate system found in the literature (Gregor & Powell, 1986; Ohman,
1988; Venturini and Berthon, 1988; Martin, 1986).  These models, as entered into the
equilibrium-speciation program Titrator (Cabaniss, 1987), are found below.  The
preliminary model (Venturini and Berthon, 1988) was solved with different
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concentrations of components (aluminum and citrate).   Simulated titrations from the
model over a broad range of pH were produced that were used to select a number of
distinct species to be sought by NMR investigations.  More models were then
developed, and some rejected on the basis of the NMR results.  A final model deemed
most suitable based on the evidence gathered was then selected in order to extrapolate
from the experimental conditions to physiologic conditions of pH and concentration.
Equilibrium constants were added to account for reaction of aluminum with ligands in
serum other than citrate.
A. Experimental
1. Aluminum and citrate solutions
Test solutions were prepared by adding either A1K(S04)2 or trisodium citrate salts (or
both; Aldrich Chemical Co., Milwaukee, WI) to distilled water and stirring overnight
to ensure that equilibrium had been reached.  The pH of these solutions was
monitored with an Orion digital pH meter (Cambridge, MA).
2. Titrations
In order to establish the amount of acid or base required to reach a given target pH
and to reach an endpoint, titration curves were prepared by adding 1.0 or 0.5 M HCl
or (standardized) NaOH solution dropwise from a buret to a day-old aluminum-citrate
solution at the appropriate concentration. pH measurements were recorded upon
stabilization of the pH meter after each addition of acid or base.
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3. Serial pH-NMR titration
This experiment was designed to look, using NMR, at the succession of aluminum
species over a range of pH.  A 1:1 aluminum-citrate solution was prepared and then
titrated gradually over a range of pH so that samples taken over that range could be
examined by NMR.   HCl was added to the 24-hour-old aluminum-citrate solution to
bring the solution to low pH, and then NaOH was added to adjust to high pH.
Aliquots of the solution were removed at appropriate pH intervals and transferred to
sample tubes.  The pH in each sample tube was measured again at least 5 minutes
post-removal from the titration vessel in order to account for drift.
4. pH-time experiments
These experiments examined the behavior of the pH of aluminum-citrate solutions
over time after addition of a large volume of base.  NaOH was added to equimoiar
aluminum-citrate solutions of 0.1 or 0.01, at mole ratios of 1 to 1.5 hydroxide to
aluminum.  pH was measured before adding base and at various points up to 24 hours
afterward.
5. NMR investigations
The NMR instrument used was a Bruker MSL 360, which is designed to handle broad
signals such as those from "Al.  The frequency used to detect the "Al nucleus was
93.839 MHz.
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Solutions for NMR experiments were decanted into specially modified rubber-
stoppered polystyrene test tubes instead of glass tubes, to avoid a possible background
aluminum signal.
a.        Preparation of standards
The AP* standard was prepared by dissolving A1K(S04)2 in water and adding 1.0 M
HCl to reach pH ~2.  The high-pH aluminum standard (Al(OH)4) was obtained by
dissolving the same salt in NaOH to pH "13.  Both standards were used to calibrate
the NMR for each experiment.  The AP^ standard had a shift of 0 ppm; Al(OH)4 was
found at 80 ppm relative to AP"^ (see Figs. 1 and 2).
h.        Kinetic NMR experiments
In order to examine the formation of aluminum-citrate species over time, 1.25 ml of
NaOH were added to 10 ml of equimolar aluminum-citrate solution (0.1 or 0.01 M)
and mixed for 20 seconds, then 2 ml were rapidly removed to a sample tube and
inserted into the NMR, which began scanning within a minute after mixing of the base
was complete.  pH was measured in the tube and in the mixing vessel after the NMR
experiment was completed.
B. Equilibrium modeling of the aluminum-citrate system
Titrator (Cabaniss, 1987) is a program for personal computers that calculates
equilibrium speciation of solutions from formation constants, total starting
concentrations of components and initial guesses at final (equilibrium) concentrations
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of components.   The program utilizes a Newton-Raphson algorithm to produce
iteratively solutions to systems of equations.   Titrator was used in these investigations
to simulate titration of equilibrium solutions over a range of pH; from these data
predominance diagrams were constructed relative to the total aluminum content of
each solution.
Sets of equilibrium constants used in modeling were from Gregor and Powell (1986);
Martin (1986); Venturini and Berthon (1989); and Ohman (1988); equilibrium
constants and other details of the models can be found in the Appendix.   Models were
run on Titrator using the following conditions;  0.1 M total aluminum: 0.1 M total
citrate (ionic strength = 0.2 M) or 0.01 M total aluminum: 0.1 M total citrate (ionic
strength = 1.1 M).  The physiologic conditions used in the final Ohman model were
99 juM citrate and 3 ^M aluminum.
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XII.       Results
A. Experimental results
Results from the first, exploratory NMR experiments are given in Table II.   A total of
five resonances were found; a change in pH in the 10:1 citrate:aluminum solution
from ~4 to ~8 produces at least two different species.   The peak seen in the 1:1
solution was broad enough to have obscured smaller peaks beneath it.
Table 11.   Major resonances observed from aluminum-citrate solutions'
Solution pH Shift(s)
l.OMCi, 0.1 M Al 4.32 15.13; 16.46
1        l.OMCi, 0.1 MAI 7.87 25.7
0.1 MCi, 0.1 MAI 3.53 10.75; ca. 0 (2 peaks: AP+ and a
broad peak)                      |
Table III.   Resonances observed with an equimolar (0.1 M) aluminum-citrate solution
over a broad range of pH.
1                    pH Shift(s) (relative to AP")
1                  2.58 0.056 (A13+)7.669 (broad, small to medium)
0.5
Standard peaks for Al^* at 0 ppm and for A1(0H)4" at 80
ppm. pH values were taken at time of mixing and and
were probably between 0.2 and 0.4 pH units lower upon
reaching the NMR (higher in the pH 7.87 sample).
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1                    PH Shift(s) (relative to AP^)
1                    ^'^
1
0.1099
ca. 0 (broadening toward base of A?^ peak)
ca. 7.5 (broadened shoulder on next peak        (10.49);
remnant of 7.669 peak at
previous sample
10.48 (fairly large, broad)                                                         |
1                    ^-^ 0.1002 (APO                                                                             1ca. 1 (broadening around base of AP"^ more        obvious)
10.8713 (a lot bigger than prev. sample)
4.96 1.77
10.9195 (ca. twice as big as lower peak)                                   ||
7.08 1.78                                                                                                110.93 (ca. twice as big as lower peak)                                       |
8.02 2.0049
10.8062 (ca. twice as big as lower peak)
1                  8.98 2.039810.8057 (ca. twice as big as lower peak; looks a           little
broader than earlier samples)                                                     ||
9.96 -.1780
10.748
79.86 (Al(OH),)                                                                          1
Table III shows chemical shifts observed in a 1:1 aluminum-citrate solution over a
range of pH values.   There appear to be at most five species here:  AP' at 0 ppm
(Fig. 1), two possible aluminum-citrate complexes at about 0.5 and 7.7 ppm, the
species with two resonances at 1 and 10 ppm (Fig. 3), and AKOH)/ at about 80 ppm
(Fig. 2).   Al(OH)4 appears at pH 9.96 (again, the actual pH was probably higher) in
the second NMR experiment, but not in the 8.98 sample; it is probably formed
somewhere in between those pH values (Figs. 3a-h).
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In the third non-kinetic NMR experiment we look at low pH values, but the resolution
was poor; there was one very broad peak downfield of the Al'"^ peak that moved from
about 8 to about 11 ppm, with another signal gradually growing on top of the AP"^
peak (data not shown).
B. Appearance of species over time
Base was added at ratios of 1.0, 1.25, and 1.5 to a 1:1 Al:Ci solution (0.1 M), which
caused the pH to bounce up quickly, then somewhat more slowly drift downward, in
the case of the 1.0 and 1.25 base:metal solutions, and upward in the 1.5 base:metal
solution (Fig. 11).  Most of the pH change took place after the first five minutes of
mixing; this also occurred when the concentrations of base, metal and ligand were
reduced tenfold (Fig. 4).
When NMR was run on the aluminum:citrate:base solution, starting at about 55
seconds after addition of base, the major signal (ca. 10 ppm) that dominated
throughout the experiment had already appeared (Fig. 5; the sharp peak is Al(OH)4,
as an internal standard).  The shift did not change with time (r^ = 0.007; Fig. 6).
Exact quantitation is not feasible at this point, despite the inclusion of an internal
standard, because the areas of sharp and broad signals cannot be reliably compared
(Akitt, 1989).
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'^8- 4   Change in pH over time after addition of different volumes of base to equiraolar aluminumrcitrate
solutions.
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C. Modeling results
Distributions of aluminum across different species predicted from published models,
run over the range of pH from 2 to 10, and at concenfrations that match those used
for our NMR investigations, are shown in Figs. 7-10.
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XIII.     Discussion
A. pH of solutions
Aluminum in solution causes the release of protons from water, resulting in an acidic
solution.  Similarly, the formation of aluminum-citrate complexes containing hydroxy
moieties releases protons.   The higher the number and concentration of
hydroxo-aluminum-citrate complexes (particularly polynuclear ones) predicted by a
model, the lower its unamended pH should be.  Therefore, the starting pH of
aluminum-citrate solutions should be a key piece of evidence for or against the
existence in significant quantities of such species and, by extension, the validity of the
models.
1.     Agreement with literature
The literature refers to very few actual starting pH measurements for the various
titrations described.   Ohman measured pH ~2 for an acidic solution of 0.01 M each
aluminum and citrate, but used citric acid instead of trisodium citrate.  In the present
experiments, the 1:1 aluminum-citrate solutions at 0.1 M using sodium citrate and
A1K(S04)2 gave a starting pH around 2.8; with citric acid a pH of around 1.8 was
obtained.  These pH values were rather hard to reproduce, and this is confirmed by
observations in the literature (Ohman, 1988; Gregor & Powell, 1986, e.g.).
71
The cessation of change in pH over time (after 20-24 hrs, according to both Ohman
and our experiments) was taken by Ohman to indicate that equilibrium has been
reached.  This assumption was confirmed by us in a kinetic NMR study that showed
the shift of the major signal in a 1:1 solution to be constant over 24 hours (Fig. 6).
2.     Agreement with models
The models made up of stability constants from various literature sources, as solved
using Titrator, were the primary source of information on starting pH (Table IV).
Models that include one or more polynuclear aluminum species, such as Ohman's,
predict a lower starting pH than those without such species (for example, Martin and
Gregor & Powell).  Potassium-citrate ion pairing has little effect on starting pH.
Table IV.  Predicted starting pH, from simulations based on literature constants, for
Al:Ci 1:1, 0.1 M solution, compared to our measurements.
Source 1-------------------------------------------Predicted starting pH
Ohman (1988) (based on solution of HjCi
instead of NajCi)
1.46
Gregor and Powell (1986), w/ K-Ci:
w/o K-Ci:
4.4
4.6
Venturini and Berthon (1989) 2.5
Martin (1986) 4.7
DeVoto and Shuman, actual measurements 2.8 (NajCi)
l.8(H,Ci)
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3.     Change of pH with time
As mentioned above, we do not know the stability of a solution's pH necessarily
indicates that the solution has reached equilibrium.  We followed the pH of several
solutions over time in order to see if we could use pH to predict kinetic behavior and
attempt to correlate it with the appearance of species as evidenced by NMR.
Ohman studied the pH change of solutions to which were added different amounts of
base and found that below a certain ratio of base to metal concentration, the solution
was able to neutralize enough hydroxide ions to allow the pH to go down again.
Above 1.33 base:metal, the pH drifted upward instead of downward; our results were
similar (Fig. 5).
Our pH-time experiments showed not only a rapid equilibration to a species believed
to remain the same over time, but also were consistent with the proposed
stoichiometry of the base- aluminum-citrate reaction.  Aluminum in the form of
Al(H20)6''^is believed to lose four protons upon hydrolysis, which can be neutralized
by one citrate ion (Cit') and one hydroxide ion; neutralization should be reached by a
hydroxide:aluminum ratio of 1.33:1.  Base:aluminum ratios of 1.0 and 1.25 resulted
in an acidic pH, indicating that the moles of base added were inadequate to neutralize
the aluminum, whereas a ratio of 1.5 resulted in solutions of alkaline pH, representing
an excess of base.  The 1.33 ratio which, again, should have resulted in a neutral-pH
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solution, in fact ended at high pH, which may have resulted from accidental addition
of excess base.
As discussed earlier, Ohman (1988) predicted that his proposed asymmetrical
trinuclear aluminum species (Al3Ci3(OH)4^; Fig. 11) came to predominance by about 5
minutes in a 1:1 aluminum-citrate solution.  We attempted to confirm these results by
examining, via NMR, the appearance over time of the trinuclear aluminum-citrate
species.   Using lower concentrations of metal and ligand (0.01 M each, as Ohman
used) and adding the appropriate amount of base did not allow us to detect the
appearance of the trinuclear species.   When we attempted to go down in concentration
of aluminum, the signal was all but lost.  Furthermore, reducing concentrations
tenfold did not appear to slow the change in pH.
The pH-change experiments also confirmed the importance of remeasuring pH in the
sample tubes at least 5 or 10 minutes after adding base, which allows the sample pH
to stabilize.
B. Species examined by NMR
Table V summarizes previously determined "Al-NMR data for the aluminum-citrate
system.  Several of the shifts reported do not agree either with one another or with
ours, but the methods given for these experiments were not sufficiently detailed to
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allow us to determine whence the differences arise.
Table V.   NMR shifts from published investigations of the aluminum-citrate system.
1 Species Shift (ppm) Reference
1 AKHjOy^, 0 Bertsch (1989)Fatemi et al. (1991)
aluminum-citrate solution
(conditions unspecified)
8, 10, 12 Akitt (1989)
A1(0H)4- 80 Fatemi et al. (1991)
Al3Ci3(OH)4^ 0, 10, 12 Feng et al. (1990)
aluminum-citrate solution
(conditions unspecitied; no
significant change noted
between different mole
ratios
14, 21.1, 28.1 Greenaway (1986)
equimolar aluminum-citrate pH 2: 0, 8 ppm
pH 3: 10 ppm
Karlik et al. (1983)
equimolar aluminum-citrate
1 (0.1 Meach)
pH 2.7: -4 ppm
pH 11.4: -87 ppm
Toy eLal. (1973)
We have used AP^ as our major reference species for the NMR experiments.  The
literature is in good agreement that, when an aluminum salt (A1K(S04)2 in our case) is
added to an already acidic solution (we used 0.5 M HCl, and Al at a concentration of
0.1 M), the major aluminum species formed is A1(H20)6'^, or AP"^.  In NMR, this is
confirmed by a very narrow peak that indicates symmetrically arranged, identical
ligands on the "Al nucleus (octahedral in this case).
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AP^ is predicted in the 1:1 aluminum-citrate system to appear at very low pH by
most of the models we have worked with.  It generally disappears, however, by about
pH 2.5, and is lost completely by about pH 3.   Our NMR data appear to conflict with
these predictions:  we found AP"^ as high as pH 3.5.   AP^ is not expected to be
present at all at such a high pH, let alone at concentrations comparable to the other
species present in solution.  It is possible that the equilibrium constants for the
aluminum-citrate species are overestimated, which would predict AP* to taper off at
lower pH than it does.   We do not fully understand the extent to which we are able to
quantify the relative concentrations of aluminum species by integrating NMR signals.
AP"^ forms a tall, narrow singlet, while the presumed aluminum-citrate complexes
form very broad resonances, whose areas are much greater than that of AP"^ alone, at
the same concentrations.
Curiously, the two major resonances at about 1 and 10 ppm have the same relative
sizes (about 2 to 1) throughout.  None of the models, however, show two species that
exist simultaneously over the wide, intermediate pH range (about 3 to 10) where these
peaks occur.  We reasoned, therefore, that these signals must represent one species
with two kinds of Al nuclei that would produce different shifts. A trinuclear species
postulated by Ohman seemed appropriate: Al3Ci3(OH)4*' (Fig. 11), referred to by
Ohman as -13,3,3.  This species has two of its aluminum nuclei in similar ligand
environments and a third in a significantly different one, which would explain the
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apparent 2-to-l mole ratio of the signals.  The existence of this species was confirmed
by ^'Al-NMR analysis and x-ray crystallography by Feng et al. (1990).  These
researchers were able to distinguish three resonances for the species, at about 0, 10,
and 12 ppm; our broad signal had a shoulder slightly downfield that is consistent with
overlapping peaks at 10 and 12.
In summary, there appear to be at most five species here:  A?^ at 0 ppm, two possible
aluminum-citrate complexes at about 0.5 and 7.7 ppm, the two-peaked species at 1
and 10 ppm, and Al(OH)4 at about 80 ppm.  Going back to the previous experiment,
for the 10:1 Ci:Al solution, adds two more species to the list: one at 15-16 ppm and
another at 25.7 ppm, for a subtotal of seven species.
The predominance of the trinuclear species from pH 3 to 9 for 1:1 aluminum to citrate
is consistent with Ohman's model, as is the appearance of Al(OH)4 at high pfl.  In
the model, however, Al(OH)4 does not appear until a higher pH is reached.
Furthermore, a second trinuclear species (AljCijCOH)!/"), referred to by Ohman as -
16,3,3; see Fig. 12) appears in the model around pH 9 for which we could see no
experimental evidence at this mole ratio; it is possible that this species takes more
time to appear than the Al3Ci3(OH)4'^species.  The -16,3,3 species is a symmetrically
arranged species that would probably give a single NMR resonance rather than the 2-
to-1 double signal observed for the -13,3,3 species.
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Tentative structure for the species (-16,3,3)^" based on an
assumed resemblance with pure AJ hydrolysis.     (from Ohman,   1988)
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The broad NMR peak may have obscured a smaller one (i.e., two species may have
been present) but the -13,3,3 species at 0 and 10 ppm was almost certainly not
present.  This suggests that the species predicted to appear around pH 9 (-16,3,3) and
A10H(H.iCi)\ designated as -5,1,1 in the figures) actually are formed at lower pH.
The third non-kinetic NMR experiment examined a narrow range of low pH values, in
an attempt to distinguish among the predicted species with a small range of
predominance.   The resolution was poor; there was one very broad peak downfield of
the AP"^ peak that shifted from about 8 to about 11 ppm, with another signal gradually
growing on top of the AP"^ peak.  The shape of both of these peaks was at times
asymmetric, suggesting that minor species might be appearing, but that their signals
were largely being blurred.  Given proposed structures for species in this pH range, it
is not surprising that a number of peaks should show up within a fairly narrow range
of ppm of one another.   In Ohman's model, two species, AlCiH"^ and AlCi°, appear at
almost the same pH (though AlCi" is expected to dominate between pH 2 and 3), and
might not be expected to produce very different NMR signals.
C.        Choice of final model
We selected a final model with which to make predictions for physiological conditions
based on agreement with our experiment.  The strengths and weaknesses of the
various models considered are described here.
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1. Gregor & Powell (1986)
This model does not include the trinuclear species suggested by the experimental
work.  Furthermore, the version of the model that considers ion-pairing disagrees with
the NMR data in that three distinct species appear between pH 3 and 9 in the 1:1
aluminum:citrate model, as opposed to the one species that appeared in our NMR
experiment.   Its predicted starting pH is not in agreement with our data.
2. Martin (1986)
Martin's model does not include the trinuclear species, and the predicted starting pH
does not agree with our data.
3. Venturini & Berthon (1989)
The starting pH predicted by this model agrees reasonably with ours.   However, the
model does not predict the trinuclear species to predominate at lower pH, as our NMR
experiments showed.
4. Ohman (1988)
The starting pH predicted by this model is lower than that measured in our
experiments; this may be because Ohman used citric acid as a component rather than
sodium citrate.  The predictions at high concentrations correspond fairly well to the
NMR results, as discussed above.
It is possible that some modification of the equilibrium constants in Ohman's model
would allow still better agreement with the NMR results.
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D. Extrapolation of Ohman's model to physiologic conditions
Fig. 13 shows the predicted species distribution for the aluminum-citrate system at
physiological pH and concentrations of citrate and aluminum.   This model predicts the
neutral species AlCi" to predominate only below pH 3.5; at higher pH the predominant
aluminum species are AlCiH (pH 3.5-6.5) and AlOH(HiCi)^- (pH 6.5-8.5).   The
trinuclear aluminum species is not thermodynamically favored at this mole-ratio.
Al(0H)3(aq) (data not shown) constituted less than 1 % of total aluminum at
physiologic pH.   In summary, no neutral lipophilic aluminum species are expected to
form under plasma conditions.
XIV.     Conclusions
The purpose of these experiments and modeling is to determine whether or not, at
physiologic pH and serum concentrations of the most important ligands for aluminum,
any neutral, lipophilic species of aluminum exist that could be absorbed passively by
target tissues and at appreciable concentrations.  Based on the model of the
aluminum-citrate system selected and plasma concentrations of the important
components, the only lipophilic species existing at appreciable quantities is AlCi"
which, however, is not believed to form at serum pH.  The major citrate species at
serum pH is AljCiaCOH)^, which as a charged molecule should not be passively
absorbed.   AlCi° may be important with regard to the gastrointestinal absorption of
aluminum, but the chemical composition of the gut is highly variable and so we have
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Fig.   13 Physiologic conditions, after model of Ohmon
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not attempted to characterize it here.   Further work could involve inclusion of
aluminum-phosphate species in the modeling and assembly of phosphate, citrate,
hydroxide, and transferrin species into a general model of aluminum speciation in
plasma.
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Appendix.   Equilibrium models used
for calculating distribution diagrams
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Harris 10:58 am   May 17, 1993
contains data from Harris (1992)
wo kinds of transferrin
ne kind of transferrin: 49 uM
# Name CI  Charge
1 Al 1 3
2 albumin 1 -1
3 cistine 1 0
4 citrate 1 -3
5 glycine 1 0
6 glutam. 1 0
7 histid. 1 0
8 lactate 1 0
9 Mg+2 1 2
10 oxalate 1 0
11 HP04- 1 -1
12 S04 1 -3
13 Tf-C 1 -3
14 Zn+2 1 2
15 Tf-N 1 -3
a.L Components: Harris
Total Initial Log Free Error
3 . OOOOOE-06 -20.000 0.000 O.OOOOOE+00
6 .30000E-04 -5.000 0.000 O.OOOOOE+00
1 . 09000E-05 -12.000 0.000 O.OOOOOE+00
9 . 90000E-04 -5.000 0.000 O.OOOOOE+00
2 .30000E-05 -5.000 0.000 O.OOOOOE+00
6 . OOOOOE-04 -6.000 0.000 O.OOOOOE+00
7 .70000E-04 -6.000 0.000 O.OOOOOE+00
1 51000E-03 -4.000 0.000 O.OOOOOE+00
5 80000E-04 -10.000 0.000 O.OOOOOE+00
9 20000E-06 -8.000 0.000 O.OOOOOE+00
1 lOOOOE-03 -5.000 0.000 O.OOOOOE+00
3. 30000E-04 -5.000 0.000 O.OOOOOE+00
3. 70000E-05 -5.500 0.000 O.OOOOOE+00
1 OOOOOE-05 -10.000 0. 000 O.OOOOOE+00
1. 20000E-05 -6.000 0.000 O.OOOOOE+00
monic Strength =   0.00000onvergence achieved in 0 iterations.
Equi librium Spec ies: Harris
# Name CI A a c c g g h 1 M o Log K Molarity
1 1 i i 1 1 i a g X
b 5 t y u s c + a
u t r c t t t 2 1
1 AlCi 1 1 0 0 1 0 0 0 0 0 0 7.980 O.OOOOE+00
2 AlCiOH 1 1 0 0 1 0 0 0 0 0 0 4.670 O.OOOOE+00
3 AlCi2 1 1 0 0 2 0 0 0 0 0 0 12.440 O.OOOOE+00
4 AlCi20H 1 1 0 0 2 0 0 0 0 0 0 6.680 O.OOOOE+00
5 AlCi20H2 1 1 0 0 2 0 0 0 0 0 0 -0.420 O.OOOOE+00
6 A13C30H4 1 3 0 0 3 0 0 0 0 0 0 17.680 O.OOOOE+00
7 A1(0H)2 1 1 0 0 0 0 0 0 0 0 0 -10.220 O.OOOOE+00
8 A1(0H)3 1 1 0 0 0 0 0 0 0 0 0 -15.730 O.OOOOE+00
9 A1(0H)4- 1 1 0 0 0 0 0 0 0 0 0 -23.600 O.OOOOE+0010 A1P04 1 1 0 0 0 0 0 0 0 0 0 14.100 O.OOOOE+0011 A1P040H 1 1 0 0 0 0 0 0 0 0 0 8.370 O.OOOOE+0012 AlGly 1 1 0 0 0 1 0 0 0 0 0 7.610 O.OOOOE+OO13 AlLac 1 1 0 0 0 0 0 0 1 0 0 2.400 O.OOOOE+001" AlLacOH 1 1 0 0 0 0 0 0 1 0 0 -0.650 O.OOOOE+00¥5 AlOx 1 1 0 0 0 0 0 0 0 0 1 6.100 O.OOOOE+00
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Greg. Pow. + K-Cit 10:46 am   May 17, 1993
^ame as Gregor/Powell model but includes K-Cit ion pairing
# Name
Chemical Components: Greg. Pow. + K-Cit
CI  Charge       Total       Initial     Log Free
1 Al 1 3 l.OOOOOE-01 -8.000 0.000
2 ci 1 -3 l.OOOOOE+00 -3.000 0.000
3 H 1 1 O.OOOOOE+00 -6.000 0.000
4 K 1 1 l.OOOOOE-01 -2.000 0.000
Error
O.OOOOOE+00
O.OOOOOE+00
O.OOOOOE+00
O.OOOOOE+OO
•^nic Strength =    0.00000
Convergence achieved in 0 iterations,
# Name
Equilibrium Species: Greg. Pow. + K-Cit
01   A   C   H   K
1   i
Log K Molarity
1 CiH 1 0 1 1 0
2 CiH2 1 0 1 2 0
3 CiH3 1 0 1 3 0
4 AlCi 1 1 1 0 0
5 AlCiH 1 1 1 1 0
6 AlCi2 1 1 2 0 0
7 AlOH 1 1 0 -1 0
8 A10H3 1 1 0 -3 0
9 AlCi20H 1 1 2 -1 0
10 AlCi20H2 1 1 2 -2 0
11 A1(0H)4 1 1 0 -4 0
12 A1(0H)2 1 1 0 -2 0
i? AlCi2H 1 1 2 1 0
m KCit-3 1 0 1 0 1
5,.900 0,.OOOOE+00
10,.250 0,.OOOOE+00
13,.160 0,.OOOOE+OO
8,.350 0..OOOOE+00
11,.020 0,,OOOOE+00
13,.360 0..OOOOE+OO
-4.,970 0,,OOOOE+OO
15,.000 0.,OOOOE+OO
7.,330 0, OOOOE+OO
0.,240 0. OOOOE+OO
23.,200 0. OOOOE+OO
10. 100 0. OOOOE+OO
17. 320 0. OOOOE+OO
5, 850 0. OOOOE+OO
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Greg. Pow. only 10:46 am   May 17, 1993
Contains only K's found in Gregor/Powell model—i.e., no A12Ci20H2,
A13Ci30H4
# Name
1 Al
2 Ci
3 H
Chemical Components: Greg. Pow. only
CI  Charge       Total       Initial     Log Free
1
1
2
l.OOOOOE-01
2.00000E-01
O.OOOOOE+00
Error
8.000 0.000 O.OOOOOE+00
3.000 0.000 O.OOOOOE+00
1.000 0.000 O.OOOOOE+00
i^nic Strength =   0.00000nvergence achieved in 0 iterations.
# Name CI A
1
Equilibrium Species: Greg. Pow. only
C  H
i
Log K Molarity
1 CiH 1 0 1 1
2 CiH2 1 0 1 2
3 CiH3 1 0 1 3
4 AlCi 1 1 1 0
5 AlCiH 1 1 1 1
6 AlCi2 1 1 2 0
7 AlOH 1 1 0 -1
8 A10H3 1 1 0 -3
9 AlCi20H 1 1 2 -1
10 AlCi20H2 1 1 2 -2
11 Al(OH)4 1 1 0 -4
12 Al(OH)2 1 1 0 -2
13 AlCi2H 1 1 2 1
5.900
10.250
13.160
8.350
11.020
13.360
-4.970
-15.000
7.330
0.240
ͣ23.200
ͣ10.100
17.320
O.OOOOE+00
O.OOOOE+00
O.OOOOE+00
O.OOOOE+00
O.OOOOE+00
O.OOOOE+00
O.OOOOE+00
O.OOOOE+00
O.OOOOE+00
O.OOOOE+00
O.OOOOE+00
O.OOOOE+00
O.OOOOE+00
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Martin model 10:46 am  May 17, 1993
•^Contains stability constants for Al/Ci system from Martin (1986)ntains no polynuclear or mixed hydroxide spp.
# Name
1 Al
2 Ci
3 H
Chemical Components: Martin model
CI  Charge       Total
1
1
2
3
-3
1
l.OOOOOE-06
l.OOOOOE-04
O.OOOOOE+00
nitial Log Free Error
-10.000 0.000 O.OOOOOE+00
-6.000 0.000 O.OOOOOE+OO
-1.000 0.000 O.OOOOOE+00
*nic Strength =   0.00000
Convergence achieved in 0 iterations.
# Name CI A
1
Equilibrium Species: Martin model
C
i
H Log K Molarity
1 CiH 1 0 1 1
2 CiH2 1 0 1 2
3 CiH3 1 0 1 3
4 AlCi 1 1 1 0
5 AlCiH 1 1 1 1
6 AlCi2 1 1 2 0
7 AlOH 1 1 0 -1
8 Al(OH) 4 1 1 0 -4
9 Al(OH)2 1 1 0 -2
10 AlCiH-•1 1 1 1 -1
3 .000 0 .OOOOE+00
7 .400 0 . OOOOE+00
13 .200 0 .OOOOE+00
8 000 0 OOOOE+00
7 700 0 OOOOE+00
13 000 0, OOOOE+00
-5. 500 0. OOOOE+00
23. 200 0. OOOOE+00
11. 100 0. OOOOE+00
4. 600 0. OOOOE+00
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Venturini & Berthon 10:47 am  May 17, 1993
Basic V&B model, no modifications, for Al/Ci/OH system
# Name
1 Al
2 Ci
3 H
Chemical Components: Venturini & Berthon
Cl  Charge       Total       Initial     Log Free
1
1
1
3
-3
1
l.OOOOOE-01
l.OOOOOE-01
O.OOOOOE+00
Error
8.000 0.000 O.OOOOOE+00
6. 000 0. 000 O.OOOOOE+00
3.000 0.000 O.OOOOOE+00
tnic Strength =   0.00000bnvergence achieved in 0 iterations.
# Name Cl A
1
Equilibrium Species: Venturini & Berthon
C  H Log Ki Molarity
1 CiH 1 0 1 1
2 CiH2 1 0 1 2
3 CiH3 1 0 1 3
4 Alci 1 1 1 0
5 AlCiH 1 1 1 1
6 AlCi2 1 1 2 0
7 AlOH 1 1 0 -1
8 A10H3 1 1 0 -3
9 AlCi20H 1 1 2 -1
10 AlCi20H2 1 1 2 -2
11 A12C20H2 1 2 2 -2
12 A13C30H4 1 3 3 -4
5.539
9.787
12.643
8.246
10.502
13.068
-3.167
-14.315
6.777
-0.209
12.694
15.085
O.OOOOE+00
O.OOOOE+00
O.OOOOE+00
O.OOOOE+00
O.OOOOE+00
O.OOOOE+00
O.OOOOE+00
O.OOOOE+00
O.OOOOE+00
O.OOOOE+00
O.OOOOE+00
O.OOOOE+00
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new Ohman 10:47 am  May 17, 1993
Contains model from Ohman (1988), using H3Cit as component
#
# Name
1 H3Cit 1 0
2 Al 1 3
3 H 2 1
Chemical Components: new Ohman
CI Charge       Total
l.OOOOOE-01
l.OOOOOE-01
O.OOOOOE+00
litial Log Free Error
-2.000 0.000 O.OOOOOE+00
-2.000 0.000 O.OOOOOE+00
-1.000 0.000 O.OOOOOE+00
tnic Strength =   0.00000onvergence achieved in 0 iterations,
Equilibrium Species: new Ohman
# Name Cl H
3
C
i
A
1
H
1  H2Cit 1 1 0 -1
2  HCit 1 1 0 -2
3  Cit3- 1 1 0 -3
4  AlOH 1 0 1 -1
5  A1(0H)2 1 0 1 -2
6  A1(0H)3 1 0 1 -3
7  A1(0H)4 1 0 1 -4
8  A13(0H)4 1 0 3 -4
9  AlHCit 1 1 1 -2
10 AlCi 1 1 1 -3
11 Al(Cit)2 1 2 1 -6
12 AlHCi- 1 1 1 -4
13 AlOHHCi 1 1 1 -5
^k  Al30HHCi^5 A13 7- 1 3 3 -131 3 3 -16
Log K
-2.769
-6.850
-12.067
-5.520
-11.300
-17.300
-23.460
-13.570
-2.680
-4.920
ͣ12.530
-8.480
-14.710
-21.770
ͣ47.110
Molarity
O.OOOOE+00
O.OOOOE+00
O.OOOOE+00
O.OOOOE+00
O.OOOOE+00
O.OOOOE+00
O.OOOOE+00
O.OOOOE+00
O.OOOOE+00
O.OOOOE+00
O.OOOOE+00
O.OOOOE+00
O.OOOOE+00
O.OOOOE+00
O.OOOOE+00
100
